Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hormone therapy may improve fatty liver in menopause, small study suggests

NCT ID NCT07103603

Knowledge-focused Sponsor: Ipek B. Ozcivit Erkan, MD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examined whether menopausal hormone therapy (MHT) can improve liver function and reduce fat buildup in the liver in postmenopausal women. 44 women were split into two groups: 22 received MHT and 22 did not. After 6 months, researchers measured liver enzymes, fat levels, and fibrosis markers using blood tests and ultrasound. The goal was to see if MHT offers liver benefits during menopause.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

44 people

The number who actually took part.

Started

Oct 2024

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female participants aged 40 years or older * Postmenopausal status (defined as ≥12 months of amenorrhea) * No prior use of menopausal hormone therapy in the last 6 months * Willingness to participate and provide informed consent Exclusion Criteria: * History of liver disease, liver malignancy, or liver transplantation * Current or past alcohol consumption exceeding 20g/day * Premature ovarian failure * History of any active malignancy * Use of medications known to affect liver enzymes or fat metabolism * Current participation in another clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatic steatosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fatty liver disease metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatic steatosis Menopause Non alcholic fatty liver disease

Contacts and locations

Locations

  • Istanbul University - Cerrahpasa, Cerrahpasa Faculty of Medicine

    Istanbul, Beyoğlu, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.